Streetbeat News

PHRRF

PharmaTher Holdings Ltd

Industry

Pharmaceutical Preparation Manufacturing

Open

0.17

Mkt cap

14M

Volume

41K

High

0.17

P/E Ratio

-3.88

52-wk high

0.32

Low

0.16

Div yield

N/A

52-wk low

0.12

PharmaTher Holdings Ltd. has been granted a post-complete response letter clarification meeting with the FDA regarding their ketamine Abbreviated New Drug Application. This follows a complete response letter issued by the FDA in October 2024.

Portfolio Pulse from

November 13, 2024 | 1:15 pm

The article discusses recent developments in the field of psychedelic therapies for mental health disorders. Small Pharma's (OTC:DMTTF) Phase 1b study on DMT and SSRIs for major depressive disorder (MDD) has released new findings. TheraPsil, a Canadian non-profit, has launched an MDMA-assisted psychotherapy training program. Apex Labs' psilocybin macrodose drug protocol has been approved for a Canadian veteran's treatment-resistant depression. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has been on a slow downtrend. Other companies mentioned include GH Research (NASDAQ:GHRS), COMPASS Pathways (NASDAQ:CMPS), Mind Medicine (NASDAQ:MNMD), Enveric Biosciences (NASDAQ:ENVB), Bright Minds Biosciences (NASDAQ:DRUG), Silo Pharma (NASDAQ:SILO), Atai Life Sciences (NASDAQ:ATAI), FSD Pharma (NASDAQ:HUGE), Incannex Healthcare (NASDAQ:IXHL), Lucy Scientific Discovery (NASDAQ:LSDI), and Cybin Inc. (NYSE:CYBN).

Portfolio Pulse from Lara Goldstein

October 02, 2023 | 1:46 pm

The FDA has accepted PharmaTher Holdings' (OTCQB:PHRRF) new drug application for a racemic ketamine product, KETARX. The goal date for the drug is April 29, 2024. PharmaTher anticipates KETARX’s U.S. commercial launch and the pursuit of international approvals thereafter. The company plans to commercialize KETARX in several dosage forms in the U.S. through its partnership with Vitruvias Therapeutics.

Portfolio Pulse from Lara Goldstein

September 27, 2023 | 6:38 pm

NY-based consulting firm Research Nester predicts the global market for psychedelic substances will grow at a CAGR of around 14% over the next 12 years, reaching $12 billion by 2035. The report features key players such as COMPASS Pathways, Silo Pharma, Numinus Wellness, Cybin, Mind Medicine, PharmaTher Holdings, atai Life Sciences, Jazz Pharmaceuticals, Janssen Pharmaceuticals, and Pfizer. The growth is attributed to increased demand for psychedelic drugs to treat mental health issues, reduced production costs due to the pandemic, and increased investment in R&D.

Portfolio Pulse from Lara Goldstein

September 12, 2023 | 8:35 pm

The Usona Institute has shared positive results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for adults with Major Depressive Disorder. COMPASS Pathways (NASDAQ:CMPS) has also shared results from research on its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression. In the UK, drug policy reform is underway, with a report urging the reclassification of psilocybin mushrooms and other psychedelics to Schedule 2. Several US states are also moving reform bills concerning the study or legalization of psychedelic substances for therapeutic purposes. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.79 on September 5, recovering from the prior week’s $1.65.

Portfolio Pulse from Lara Goldstein

September 11, 2023 | 1:34 pm

PharmaTher Holdings (OTCQB:PHRRF) has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, to the FDA. The company expects an expedited review and anticipates KETARX’s approval and commercial launch in the U.S. in Q2 2024. PharmaTher is also working on international approvals to meet the growing global demand for ketamine. The company is partnering with Vitruvias Therapeutics to commercialize KETARX in the U.S.

Portfolio Pulse from Lara Goldstein

September 06, 2023 | 9:21 pm

Minneapolis Mayor Jacob Frey has signed an executive order deprioritizing criminal prosecution for possession, use, purchase, cultivation and engaging in practices with “entheogenic plants or plant compounds. German company Acid Berlin is selling a reportedly legal LSD prodrug and shipping it through DHL Group to clients based in Berlin. Reunion Neuroscience is on the brink of going private with final court approval. Filament Health gets ready to uplist to NASDAQ in a $210M SPAC deal. Sales of Johnson & Johnson esketamine drug Spravato rose nearly 100% year-over-year. PharmaTher's DMT patch showed positive outcomes, investment toward the clinical stage. Enveric Biosciences unveiled positive results from animal studies of its psilocin prodrug for anxiety. Core One Labs entered a LOI for the first sale of its psychedelic biosynthetic compounds. AdvisorShares Psychedelics ETF opened Monday, July 24, at $1.94, dropping from prior Friday’s closing at $1.99.

Portfolio Pulse from Lara Goldstein

July 24, 2023 | 9:14 pm

PharmaTher Holdings (OTCQB:PHRRF) and the Terasaki Institute for Biomedical Innovation have reported positive outcomes from their research on a novel microneedle patch for the delivery of DMT. The study aimed to develop a suitable prototype of PharmaPatch for DMT’s transdermal delivery. The company will work with its research partner PharmaDrug Inc., and invest $227,700 in PharmaDrug's subsidiary, Sairiyo Therapeutics, for a 49% ownership.

Portfolio Pulse from Lara Goldstein

July 18, 2023 | 9:45 pm

The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver, attracting over 12,000 attendees. New York Mets owner Steve Cohen announced a $5 million grant for MAPS’ ongoing clinical studies toward FDA approval of MDMA-assisted therapy for PTSD. Toms Shoes founder Blake Mycoskie pledged to donate and invest $100 million in organizations and projects advancing psychedelic-assisted therapies. SEMRush (NYSE:SEMR) analysis revealed a shift in America's consciousness towards psychedelics and cannabis. Several companies received regulatory approvals and patents, and announced partnerships and financial results.

Portfolio Pulse from Lara Goldstein

July 04, 2023 | 2:21 pm

BetterLife Pharma Inc. (OTCQB:BETRF) is fast-tracking its U.S. patent application for non-hallucinogenic LSD derivatives, including its 2-bromo-LSD derivative BETR-001, which is expected to begin clinical trials for Major Depressive Disorder. The patent covers the composition, treatment uses, and a novel production method. The company's CEO, Dr. Ahmad Doroudian, highlighted the compound's neuroplasticity properties and efficacy in preclinical models of depression, anxiety, and pain. Another biotech company, PharmaTher Holdings (OTC:PHRRF), recently fast-tracked an application for its proprietary racemic ketamine, KETARX, for the treatment of levodopa-induced dyskinesia in Parkinson’s disease.

Portfolio Pulse from Lara Goldstein

June 28, 2023 | 7:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.